How Lipitor Works on Proteins
Lipitor (atorvastatin) inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway that produces cholesterol. This enzyme is a protein directly targeted, reducing cholesterol synthesis in the liver by blocking the conversion of HMG-CoA to mevalonic acid.[1]
Which Proteins Are Downstream Targets?
Beyond HMG-CoA reductase, Lipitor disrupts production of isoprenoids, which prenylate (attach lipid groups to) small GTPases like Rho, Rac, and Ras. These proteins regulate cell signaling, inflammation, and vascular function. Inhibition leads to less prenylation, altering their membrane localization and activity, contributing to plaque stabilization and anti-inflammatory effects.[2][3]
Proteins Affected in Muscle and Other Tissues
Statins like Lipitor can reduce coenzyme Q10 (ubiquinone) levels by impairing the same pathway, indirectly impacting mitochondrial electron transport proteins (e.g., complexes I, II, III). This contributes to rare myopathy risks. Prenylation inhibition also affects ubiquitinated proteins via proteasome pathways.[4]
Evidence from Clinical Studies
Trials show Lipitor lowers CRP (C-reactive protein), an inflammation marker, via Rho GTPase effects. Proteomic studies confirm changes in over 100 plasma proteins, including apolipoproteins and adhesion molecules like ICAM-1.[5]
Patient-Reported Protein-Related Concerns
Users report muscle pain linked to reduced prenylated GTPase function, prompting questions about CoQ10 supplements. Liver enzyme elevations (ALT/AST proteins) occur in <3% of cases, resolving on discontinuation.[6]
[1]: FDA Label for Lipitor
[2]: Nature Reviews Drug Discovery on Statin Mechanisms
[3]: Circulation Journal on Rho GTPases
[4]: Journal of Clinical Investigation on Statin Myopathy
[5]: Proteomics Study in Atherosclerosis
[6]: Drugs.com Lipitor Side Effects